title: Bone strength: more than just bone density.
abstract: The following bone density measurements have limited utility in determining bone strength because they do not include bone quality: microarchitecture, mineralization, ability to repair damage, collagen structure, crystal size, or marrow composition. Patients with kidney disease have poor bone quality. Newman et al. now describe beneficial effects with raloxifene in an animal model of progressive kidney disease. These biomechanical measurements will be important in the development of medications to decrease fractures in patients.
authors.affiliation: Department of Medicine, University of Washington, Seattle, Washington, USA. Electronic address: smott@uw.edu.
authors.forename: Susan M
authors.initials: SM
authors.lastname: Ott
mesh_terms: D000818:Animals; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001842:Bone and Bones; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D020849:Raloxifene Hydrochloride